Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398933 | 0.89 | NOTUM (0.48) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL3398778 | 0.88 | ALDH1A1 (0.37) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL2302826 | 0.85 | NPC1 (0.36) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL2305366 | 0.83 | POLB (0.35) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL30025602 | 0.83 | POLB (0.35) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL3395281 | 0.81 | ALDH1A1 (0.55) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| Bicarbonate SCHEMBL28453614 | 0.80 | NPC1 (0.40) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL21054837 | 0.79 | ALDH1A1 (0.38) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL3462916 | 0.78 | MAPT (0.43) | NPC1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL2949533 | 0.77 | ALDH1A1 (0.39) | NPC1CYP1A2CYP2C19ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720438-B1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-06-03 | — | — | US | disclosed |
| WO-2020247804-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3720438-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | Amplyx Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019113542-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-2223926-B1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOXYMETHYL GROUP AND ANTIFUNGAL AGENT CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8513287-B2 | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8410277-B2 | Method for manufacturing heterocycle substituted pyridine derivatives | Eisai R&D Managment Co., Ltd. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | TANAKA KEIGO (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2226320-A1 | PROCESS FOR PRODUCTION OF HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2223926-A1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOXYMETHYL GROUP AND ANTIFUNGAL AGENT CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20090233883-A1 | HETEROCYCLIC RING AND PHOSPHONOXYMETHYL GROUP SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, GLUL, IL4I1 | NPC1 2288/4885CYP1A2 92/4885CYP2C19 254/4885 |
| US-20090233883-A1 | HETEROCYCLIC RING AND PHOSPHONOXYMETHYL GROUP SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING SAME | MTOR, ERG28, MTMR1 | NPC1 690/4885CYP1A2 411/4885CYP2C19 106/4885 |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | NPC1 194/4885CYP1A2 35/4885CYP2C19 38/4885 |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | NPC1 194/4885CYP1A2 35/4885CYP2C19 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.